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Purpose: This cross-sectional study investigated the degree of association between the 
results of ambulatory step activity monitoring (SAM), self-reported physical functioning 
(SRPF) and the 6 minute standardized walking test (6-MWT) in cancer patients with 
haematological malignancies. Method: Assessments of ambulatory SAM, SRPF and 6-MWT 
were assessed in 102 patients up to 122 days (mean 78 + 35) after hematopoietic stem cell 
transplantation (HSCT). To determine the association between measures of walking, the 
Pearson product moment correlation coefficient (r) including the 95%CI and the r2 were 
calculated. Simple linear regression analyses were performed to estimate the ambulatory 
step activity from SRPF and the 6-MWT. Results: The average age was 47 years (+12) and 
body mass index 23.4 (+4). The correlations were low between ambulatory SAM outputs and 
SRPF (ranging from -0.32 to 0.34, p<0.01), and very low between SAM outputs and 6-MWT, 
(ranging from 0.21 to 0.24). The correlation between SRPF and the 6-MWT was low (0.33, 
p<0.01). The 95%CIs were quite narrow around r. The shared variance (r2) between the SAM 
and SPPF ranged between 4% and 11% and the shared variance between the SAM and 6-
MWT ranged between 0.5% and 18%. Linear regression yielded weak relationships and 
large standard errors of estimate between the SAM, SRPF and 6-MWT. Conclusions: Self-
reported physical functioning and the 6-minute standardized walking test do not reflect daily 
walking activity. In clinical use (e.g., to evaluate the effects of a rehabilitation program), 
ambulatory step activity outputs can be considered as an additional outcome to assess day-
to-day walking activity in haematological cancer patients after HSCT. 
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Introduction  
Haematopoietic stem cell transplantation (HSCT) can be a life-saving procedure in a number 
of haematologic diseases.[1,2] However, the toxicity associated with HSCT can have a 
significant impact on patients’ functional health and symptom burden, even long after 
treatment has been completed.[3,4] Physical exercise interventions have been developed to 
reduce the debilitating treatment-related symptoms (e.g., pain, nausea, fatigue, loss of 
physical performance) in HSCT patients.[5] Beneficial effects have been reported for aerobic 
capacity, immunological function, muscle strength, fatigue and health-related quality of life.[6-
9] However, only a few studies have investigated the effects of physical exercise on physical 
functioning [8,10,11], defined as the ability to conduct a variety of activities ranging from self-
care to more challenging and vigorous activities that require increasing degrees of mobility, 
strength or endurance.[4] 
A range of tests are available to assess physical functioning in patients with chronic 
diseases.[12] The two basic approaches are self-report (i.e., questionnaire-based 
assessments) and performance-based, or laboratory-based measures.[13] Questionnaire-
based assessments are designed to capture the individual’s subjective ratings of his or her 
physical functioning, and are premised on the belief that the patient’s perception is important 
if not essential in evaluating health and response to treatment.[13] Questionnaire-based 
assessments, however, have the drawback that they depend on the accuracy of the patient’s 
perception, cognition and communication.[14,15]  
Performance-based or laboratory-based measures involve direct therapist or 
researcher observation and grading of the patient’s physical activity level.[14] One of the 
potential disadvantages of such performance-based measures is that they may capture best 
performance at a single point in time rather than usual, daily performance.[14] The level of 
effort exerted during a walking test performed under standardized conditions may differ from 
that required or attempted in daily life.[16] Usual performance or daily activity can be reliably 
assessed by microprocessor-based accelerometers.[17] This relatively new approach has 
the potential to provide a more accurate estimate of how much patients actually walk in their 
day-to-day life. [14,18]  
 Several studies have investigated the association between questionnaire-based 
assessments, standardized performance tests and usual performance assessments in 
patients with chronic diseases. A low to moderate association (r = 0.42, p< 0.05) was 
observed between standardized timed walking and an ambulatory activity monitor in post-
polyiomyelitis patients [16]. Moderate associations were observed between standardized 
timed walking and ambulatory walking activity in stroke patients (r = 0.51 to 0.73, p< 0.01 
[14] and r = 0.6 to 0.73, p< 0.001).[19] Moderate associations were also observed between a 
6-minute walking test and daily walking activity in patients with chronic obstructive pulmonary 
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disease (r = 0.60, p< 0.05 [20] and r = 0.67, p< 0.01) [21] and in patients with chronic heart 
failure (r = 0.68, p< 0.001), respectively. [22] An almost perfect association was observed 
between standardized timed walking and an ambulatory activity monitoring in patients with 
chronic heart failure (r = 0.91, p< 0.001). [23] 
A low association was reported between an ambulatory activity monitor and the 
questionnaire-based assessment of veterans using the RAND 36-item Health Survey (r = 
0.29, p = 0.002). [21] Moderate to strong associations have been reported between self-
reported physical functioning (the SF-36 Health Survey) and ambulatory walking activity (r = -
0.39 to 0.49, p< 0.01) in men with diabetes [13] and in patients with osteoarthritis r=0.5/0.6, 
p<0.01).[24] In one report, the physical activity values from the accelerometer correlated 
moderately with the Minnesota Leisure Time Physical Activity Questionnaire (r = 0.33; P < 
0.01). [25] 
No significant associations were reported between the 6-minute walking test and an 
ambulatory activity monitor in older adults residing in continuing care retirement communities 
[26] or in patients with peripheral arterial disease (p >.05) [27] No significant associations 
were observed between the Physical Activity Scale for the Elderly (PASE) and an ambulatory 
activity monitor in older adults residing in continuing care retirement communities.[26] 
Similarly, ambulatory activity monitoring did not correlate significantly with self-reported 
functional status in patients with chronic obstructive pulmonary disease. [20] 
To the best of our knowledge, only one previous report has investigated the relationship 
between ambulatory step activity monitoring, self-reported physical functioning and the 6-
minute standardized walking test in cancer patients.[28] There was moderate agreement 
between the 7-Day Physical Activity Recall and the accelerometer with longitudinal serial 
correlation coefficients of 0.54 (baseline), 0.24 (year 1), and 0.53 (year 2), all p-values <0.01.  
To summarize, the association observed between self-reported physical functioning, 
standardized timed walking and the outputs of ambulatory step activity varies from none to 
almost perfect in studies of various chronic disease populations. Only one study has 
investigated this issue in cancer patients, and none among HSCT patients. The aim of the 
current study was to determine the degree of association between self-reported physical 
functioning, standardized timed walking and the outputs of ambulatory step activity 
monitoring among outpatients with haematological malignancies recovering from HSCT. 
 
Methods 
Participants 
This study presents a cross-sectional analysis of baseline data collected from a subset of 
117 ambulatory hematological patients after completion of HSCT at the University Hospital 
Zurich and the Cantonal Hospital of St. Gallen, Switzerland. These baseline data were 
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collected before the patients were randomized between an ambulatory physical exercise 
intervention and a usual care (i.e., non-exercising) control group. Adult patients were 
considered eligible for the study if they had completed their HSCT treatment. Patients were 
excluded from the study in case of graft versus host disease (GVHD) except for grade I not 
requiring treatment, painful joints, instable osteolyses, chronic pain, lesions of the central or 
peripheral nervous system, uncontrolled cardiovascular disease, thyroid disease or diabetes. 
The study was approved by the local ethical committee. All patients provided written 
informed consent.  
 
Measurements 
 Ambulatory step activity levels were assessed with the Step Activity Monitor 3 (SAM3, 
Cymatech Corporation, Seattle, WA, USA). The patients were instructed to wear the SAM3 
for 7 consecutive days. Activity monitoring over a 7-day period has previously been found to 
result in reliable and representative measures of an individual’s movements on a day-to-day 
basis.[17] All participants were instructed to leave the SAM3 on the ankle if they had to rest 
or lay down during the day and to perform their daily activities as usual. The parameters 
assessed by the SAM3 for this study were: (1) `average steps/day`, (2) percentage time ‘with 
no step rate’, ‘at low step rate’ (between 15 and 40 steps/min.), at ‘moderate step 
rate`(between 40 and 75 steps/min.), and at ‘high step rate’ (more than 75 steps / min.), and 
(3) the `peak activity index` (calculated by ranking all minutes of the day according to the 
cadence, and then taking the highest 30 values).[13] The accuracy of the SAM3 has 
consistently been reported to be over 98%. [18] The test-retest reliability, as measured by 
ICCs for 2 consecutive 7-day recordings including the 95% CI for total steps and peak 
activity, was 0.90 (95% CI, 0.75-0.98) and 0.85 (95% CI, 0.66-0.94), respectively. [17] 
Walking distance was assessed with the six minute walking test. The 6-minute 
walking test is a widely used, reliable (ICC=.98), sub-maximal exercise test that assesses the 
physiologic and functional status in cancer patients’ [29]  
Self-reported physical function was assessed with the `physical function` scale (5 
items) of the EORTC Core Quality-of-Life Questionnaire (EORTC QLQ-C30, version 3). This 
questionnaire is a widely used, cancer-specific, patient-based and self-administered 
instrument. The EORTC QLQ-C30 has demonstrated validity and reliability when used 
among a wide range of cancer patient populations in a range of languages, including 
German.[30,31] The internal consistency (Cronbach’s alpha) and the test-retest reliability 
(Pearson’s correlation coefficient) of the physical functioning subscale are 0.81 and 0.91, 
respectively.[32]  The scale items have four response choices ranging from 1 (“not at all”) to 
4 (“very much”). Following standard procedures, the physical function scale score was 
linearly transformed to a 0 to 100 scale, with a higher score representing a better level of 
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functioning. [33] The patients were asked to report their physical functioning over the last 
seven days.  
 
Measurement procedure 
 All patients underwent a standardized 6-minute walking test and completed the 
EORTC QLQ-C30 questionnaire at the same time point during the day (late morning or early 
afternoon). Subsequently, patients were instructed to wear the SAM3 for 7 consecutive days, 
excluding sleep time. All participants were instructed to leave the SAM3 on the ankle if they 
had to rest or lay down during the day, and to perform their daily activities as usual. After 7 
days, the participants returned the SAM3 to the study centre in a pre-paid envelope. The 
SAM3 data were downloaded into a database. 
 
Descriptive measures 
Height was assessed to the nearest 0.5 cm with a wall fixed tape measure. Weight was 
assessed to the nearest 0.5 kg (SECA weighting machine, Model 791). Diagnosis and 
staging, type of donor, total body irradiation for patients with allogeneic transplantation, 
concomitant disease, time interval between haematological cancer diagnosis and walking 
assessment disease are described in Table 1. 
 
Statistical analyses 
Normality of the data was tested with the Kolmogorov-Smirnov test. Descriptive results are 
expressed as mean + SD and range (Table 1). Baseline step activity outputs, health-related 
quality of life scores and standardised timed walking measures are presented in Table II. The 
level of association between the variables of interest was assessed using the Pearson 
product moment correlation coefficient for normally distributed variables (Table 3). A 
correlation above 0.9 was interpreted as very high, 0.7 to 0.89 as high, 0.5 to 0.69 as 
moderate, 0.30 to 0.49 as low and less than 0.29 as very low or negligible.[34] The 95% CI 
intervals around the Pearson product moment correlation coefficient (r) and the R squared 
(r2) were calculated. Simple linear regression analyses, including the standard error of 
estimate, were performed to determine the relationships between the measures of walking 
activity. A p value of 0.05 was used to define statistical significance. All statistical analyses 
were performed using SPSS 17. 
 
Results 
One hundred and seventeen patients were eligible and agreed to participate. Fifteen patients 
(12.8%) were excluded from the analyses due to missing data, resulting in a final study 
sample of 102 patients (42 women and 60 men). The study sample consisted of 35 patients 
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with leukaemia, 30 with lymphoma, 33 with multiple myeloma and 4 with osteomyelofibrosis. 
The average age was 47 years (+12) and body mass index 23.4 (+4). Patients were included 
into the study and performed the walking assessments between 22 and 122 days after 
completion of treatment (mean 78 days, SD 35 days) (Table 1). All outcomes were 
distributed normally. 
The correlations were low (Table 3) between ambulatory step activity outputs and self-
reported physical function (ranging from -0.32 to 0.34, p<0.01), and very low (Table 5) 
between ambulatory step activity outputs and the 6-minute walking test, (ranging from 0.21 to 
0.24). The correlation between self-reported physical function and the 6-minute walking test 
was also low (0.33, p<0.01). The 95%CIs around the r of the walking measures were quite 
narrow (Table 3 and 5). The shared variance (r2) between the ambulatory walking activity 
and self-reported physical function varied between 4% and 11% (Table 3). The shared 
variance between the ambulatory walking activity and the 6-minute walking test varied 
between 0.5% and 18% (Table5).  
All variables in the regression model for ambulatory walking activity and self-reported 
physical function remained statistically significant, except for the `percentage of time at high 
step rate` (p>0.05, Table 4). 
The standard error of estimate for ambulatory step activity and self-reported function was 
1783 steps/day and 7.12 for peak activity. For the percentages of time with different walking 
intensities, the standard errors of estimate varied between 1.40% and 6.30% (Table 4). The 
standard error of estimate between ambulatory step activity and 6-minute walking test was 
1852 steps/day and 7.12 for peak activity (Table 6). For the percentages of time with different 
walking intensities, the standard errors of estimate varied between 1.42% and 6.56% (Table 
6). 
The associations between the other multi-item scales (4 functional scales (role, cognitive, 
emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting), and the 
global health and quality of life scale) of the EORTC QLQ-C30, the daily ambulatory steps 
and the 6-minute walking test were determined. These calculations yielded low and mostly 
non-significant correlations varying between -.267 and .282 (data not presented). 
 
Discussion 
The results of this study indicate that ambulatory daily activity as measured with a 
step activity monitor does not correlate significantly or has only a weak correlation with a 
standardized walking test or with self-reported physical functioning (the EORTC QLQ-C30 
physical functioning scale). Only 11% of the variability in daily walking activity was explained 
by self-reported physical function and 18% by the six-minute walking test. The standard 
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errors of estimate, which can be used to estimate the daily ambulatory activity from self-
reported physical function and the 6-minute walking test, were large. 
The assessment of mobility can be related to the World Health Organization 
International Classification of Functioning, Disabiltiy and Health (ICF).[35] Central concepts 
of the ICF are participation or performance, describing what an individual does in his 
environment, and activity, also referred to as capacity or the ability to execute a task or 
action. It is, thus, possible to make a distinction between three conceptually distinct levels of 
physical activity: self-reported (questions about functioning), experimental (physical 
performance) and enacted functioning (physical activity).[36] Discordance can exist between 
what people say they can do, are able to do in standard physical performance tests and what 
they actually do. Such discordance is evidenced in the results of our study.  
With the improvement of prognosis in haematological malignancies, programs to 
improve physical health through walking and other forms of physical activity may become an 
increasingly important component in continuing care programs [11,17]. Ultimately, the choice 
of which instrument or method is the best to assess patients’ level of physical activity is a 
function of the research question, participant burden and available resources to the 
researcher or the practitioner [37]. The results of this study indicate that the SAM represents 
an additional approach to assessing in more detail the physical activity behaviour of the 
HSCT patient group, that it does not cause unnecessary or excessive discomfort to the 
patients, and that it contributes information independent of that provided by self-report 
measures and in-clinic performance tests.  
Several possible limitations of the present study should be noted. First, due to the 
cross-sectional design, it was not possible to determine the degree of association in change 
scores derived from the three types of measures investigated. Second, the step activity 
monitor data for 15 patients (13% of the sample) had to be excluded from the analysis due to 
missing data (i.e., non-adherence with the continued use of the step activity monitor for 7 
consecutive days). Third, the data used in this study were based on baseline values obtained 
from HSCT patients who had agreed to take part in a randomized controlled trial 
investigating the effectiveness of a physical exercise programme. Patients who were either 
not eligible or not interested in participating in the trial were not included in this study. Those 
patients who did participate may represent a `more active` or `healthier` group of HSCT 
patients. Fourth, there was a fair degree of variability in the time at which the assessments 
took place in relation to the completion of treatment. Some patients had more time to recover 
from the side effects of high-dose chemotherapy than others (Table 1). This may have 
influenced the variation observed in the day to-day walking activity. Finally, the 95 CIs% 
around the r indicated a relatively low degree of variability for the measures of walking 
 8
activity measures, however, factors such as concomitant disease and staging may have 
biased the estimates of walking activity. 
 
Conclusions 
The use of step activity monitors adds additional and relatively independent 
information to that obtained from self-report measures of physical functioning and clinic-
based performance tests for evaluating the physical activity level of patients who have 
undergone HSCT. The use of such daily monitors is feasible, although attention needs to be 
paid to ensuring high levels of compliance with the use of such devices over an extended 
period of time (e.g., 7 days).  
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Table 1 
Baseline demographic and medical data, step activity outputs, self-reported physical function and 
standardized timed walking (n=102) female 42 (41%), male 60 (59%) 
Demographic variables 
 
Mean (Sd) 
Range 
Age (years) 47 (12) 
23 to 75 
Height (cm) 173.8 (9.3) 
152 to 197 
Weight 71.9 (13.7) 
38 to 109 
BMI (kg/m2) 23.4 (4.0) 
15 to 34 
Time interval between HSCT and assessments of 
walking activity (days) 
78 (35)  
22 to 122 
Diagnosis and staging* 
AML 
In remission before HSCT 
CLL 
Chronic phase before HSCT 
Accelerated phase before HSCT 
ALL 
In remission before HSCT 
Hodgkin 
II 
III 
IV 
NHL 
I 
II 
IV 
Multiple Myeloma 
II 
III 
Osteomyelofibrosis 
N (%)  
24 (23.5) 
17 (70.8) 
10 (9.8) 
7 (6.9) 
3 (2.9) 
1 (100) 
1 (100) 
12 (11.8) 
7 (6.9) 
2 (2.0) 
3 (2.9) 
18 (17.6) 
2 (2.0) 
11 (10.8) 
5 (4.9) 
33 (32.4) 
9 (8.8) 
24 (23.5) 
4 (3.9) 
Donor  
Allogeneic 
Unrelated donor 
Related donor 
Autologous 
ASCT 1x 
ASCT 2x 
N (%) 
 
22 (21.6) 
16 (15.7) 
 
46 (45.1) 
18 (17.6) 
Total body irradiation for allogeneic transplants 
Tbi 
No Tbi 
N (%) 
25 (65.8) 
13 (34.2) 
Time interval between hematological cancer diagnosis 
and walking assessment  
0-6 months 
6-12 months 
1-2 years 
2-5 years 
> 5 years 
N (%) 
 
3 (2.9) 
23 (22.5) 
45 (44.1) 
17 (16.7) 
14 (13.7) 
Concomitant disease 
0 
1 
2 
3 
>3 
N (%) 
11(10.8) 
27 (26.5) 
24 (23.5) 
17 (16.7) 
23 (22.5) 
Abbreviations: HSCT; Haematopoietic stem cell transplantation, AML; Acute myeloid leukaemia, CLL; 
Chronic lymphoid leukaemia; ALL; Acute lymphoid leukaemia, NHL; Non-Hodgkin lymphoma; ASCT; 
Autologous stem cell transplantation, TBI; Total body irradiation. * For detailed information concerning 
diseases and staging see [38]. 
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Table 2 
Baseline step activity outputs, Health related Quality of life scores and standardized timed walking 
(n=102) female 42 (41%), male 60 (59%) 
SAM: Average steps/day 4684 (1884) 
897 to 11744 
SAM: Percentage of time with no step rate 75.3 (6.6) 
52.4 to 93.2 
SAM: Percentage of time at low step rate 
(Between 15 and 40 steps/min.) 
14.8 (3.8) 
5.1 to 25 
SAM: Percentage of time at moderate step rate 
(Between 40 steps and 75 steps / min.) 
7.0 (3.2) 
1.5 to 21.3 
SAM: Percentage of time at high step rate 
(> 75 steps/min.) 
2.1 (1.4) 
0.1 to 7.6 
SAM: Peak activity index 41.8 (7.3) 
18.6 to 58.2 
EORTC QLQ-C30: Self-reported physical 
function 
71.2 (17.0) 
20 to 100 
STW: 6 minute walking test (meters) 575.8 (87.4) 
205 to 788 
Abbreviations: SAM; Ambulatory step activity monitoring, EORTC QLQ C-30; Quality of life 
questionnaire, STW; Standardized timed walking. 
 
 
 
 
 
 
 
 
 
Table 3: Correlations between step activity outputs and self-reported physical function 
Association r 95%CI r2 
ASD / SRPF .34* .16  to .58 .11 
% no step / 
SRPF 
-.32* -.49  to -.13 .10 
% low step / 
SRPF 
0.20# .01 to .04 .04 
 % moderate step / 
SRPF 
0.33* .15 to .50 .11 
% high step / SRPF 0.27* .08 to .44 .07 
PAI / 
SRPF 
0.24# .05 to .42 .06 
# p< 0.05, * p<0.01 
Abbreviations: ASD; average steps/day, SRPF; self-reported physical function, r; Pearson product 
moment correlation coefficient, r2; r square, % no step; percentage of time with no step rate, % low 
step; percentage of time at low step rate, % moderate step; percentage of time at moderate step rate, 
% high step; percentage of time at high step rate, PAI; peak activity index. 
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Table 4: Results of simple linear regression for step activity outputs and self-reported physical 
function 
unst.cft st.cft  
Model  B St.e Beta 
 
t 
 
p 
 
st. err. estim 
ASD 
(constant) 
2007 765.51 2.62 .010 
SRPF 37.66 
 
10.46 
 
.34 
3.60 .001 
1783 
% no step 
(constant) 
85.04 2.71 31.42 .000 
SRPF -.12 
 
0.04 
 
-.32 
-3.34 .001 
6.30 
% low step 
(constant) 
11.48 1.61 7.10 .000 
SRPF .046 .022 
 
.20 
2.09 .040 
3.76 
% moderate 
step 
(constant) 
2.60 1.32 1.97 .051 
SRPF 0.62 .018 
 
.33 
3.45 .001 
3.06 
% high step 
(constant) 
0.43 .601 .71 .481 
SRPF 0.23 .008 
 
.27 
2.81 .006 
1.40 
Peak activity 
index 
(constant) 
34.53 3.06 11.29 .000 
SRPF .10 .04 
 
.24 
2.45 .016 
7.12 
Abbreviations: ASD; average steps/day, SRPF; self-reported physical function, % no step; percentage 
of time with no step rate, % low step; percentage of time at low step rate, % moderate step; 
percentage of time at moderate step rate, % high step; percentage of time at high step rate, PAI; peak 
activity index, Unst.cft; unstandardized coefficients, St.e; standard error, st.cft; standardized 
coefficients, p; p-value, st. err. estim; standard error of estimate. 
 
 
 
 
 
Table 5: Correlations between step activity outputs and the 6 minute walking test 
Association r 95%CI r2 
ASD / 6MWT 0.21# .02  to .04 .04 
% no step / 6 MWT -.16ns -.35  to -.04 .03 
% low step / 6 MWT .07ns -.13 to .27 .005 
% moderate step /  
6 MWT 
.14ns -.06 to .33 .18 
 % high step / 6MWT 0.21# .02 to .39 .04 
PAI /  
6 MWT 
0.24# .05 to .42 .06 
# p< 0.05, * p<0.01. Abbreviations: r; Pearson product moment correlation coefficient, r2; r- square, 
ASD; average steps/day, 6MWT; 6 minute walking test, % no step; percentage of time with no step 
rate, % low step; percentage of time at low step rate, % moderate step; percentage of time at 
moderate step rate, % high step; percentage of time at high step rate, PAI; peak activity index. 
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Table 6: Results of simple linear regression for step activity outputs and 6-MWT 
unst.cft st.cft  
Model  B St.e Beta 
 
t 
 
p 
 
st. err. estim 
ASD 
(constant) 
2104.91 1228.14 1.71 .090 
6-MWT 4.48 2.11 
.21 
2.13 .036 
1852 
% no step 
(constant) 
83.30 4.35 19.17 .000 
6-MWT -.01 .007 
 
-.16 
-1.64 .104 
6.56 
% low step 
(constant) 
13.00 2.54 5.12 .000 
6-MWT .003 .004 
 
.07 
.697 .487 
3.83 
% moderate 
step 
(constant) 
4.13 2.13 1.40 .055 
6-MWT .005 .004 
 
.14 
1.37 .174 
3.21 
% high step 
(constant) 
.058 .942 .062 .951 
6-MWT .003 .002 
 
.21 
2.16 .033 
1.42 
Peak activity 
index 
(constant) 
30.48 4.72 6.54 .000 
6-MWT .020 .008 
 
.24 
2.43 .017 
7.12 
Abbreviations: ASD; average steps/day, 6-MWT; 6-minute walking test, % no step; percentage of time 
with no step rate, % low step; percentage of time at low step rate, % moderate step; percentage of 
time at moderate step rate, % high step; percentage of time at high step rate, PAI; peak activity index, 
Unst.cft; unstandardized coefficients, St.e; standard error, st.cft; standardized coefficients, p; p-value, 
st. err. estim; standard error of estimate. 
 
